Procyrion
Houston
Texas
United States
About Procyrion
Houston-based medical device firm Procyrion, Inc. is developing the first catheter-deployed, intra-aortic pump for ambulatory use. The device is designed to rest and heal the heart by reducing afterload while simultaneously improving blood flow to vital organs. This groundbreaking cardiology tool, conceived by cardiologist Dr. Reynolds M. Delgado, III, medical director of Mechanical Support Devices in Heart Failure at the Texas Heart Institute, is expected to provide a minimally invasive treatment option for millions of chronic heart failure patients.
YEAR FOUNDED:
2005
LEADERSHIP:
Founder and CMO: Reynolds M. Delgado III
CEO: Benjamin A. Hertzog
COO: Jason Heuring
8 articles about Procyrion
-
Procyrion Closes $57.7 Million in Series E Financing
2/5/2024
Procyrion™, Inc. announced today the completion of a $57.7 million Series E funding round, including the conversion of $10.0 million of interim financing.
-
Procyrion Announces First Patient Enrollments in the DRAIN-HF Pivotal IDE Trial for Aortix™ Percutaneous Mechanical Circulatory Support Technology
11/30/2023
Procyrion, Inc. announced the enrollment of the first patients in the company's IDE pivotal trial.
-
Procyrion Secures New Medicare Payment Codes Applicable to its Aortix™ Percutaneous Mechanical Circulatory Support Technology
9/7/2023
Procyrion, Inc. announced it has successfully secured new inpatient hospital ICD-10-PCS procedure codes applicable to its Aortix™ percutaneous mechanical circulatory support technology.
-
Aortix Pump Therapy Leads to Rapid Decongestion and Improved Kidney Function in Hospitalized Patients with Heart Failure and Worsening Renal Function
3/21/2023
Procyrion, Inc. announced that use of its Aortix™ percutaneous mechanical circulatory support device led to rapid decongestion in a pilot study of patients admitted to the hospital with acute decompensated heart failure and worsening renal function, which is known as cardiorenal syndrome.
-
Procyrion Announces Successful First-in-Human Cases with Aortix Pump to Prevent Acute Kidney Injury in Patients Undergoing Cardiac Surgery
2/22/2023
Procyrion, Inc. announced today successful treatment of the first patients in the A PRIORI (Aortix therapy for Perioperative ReductIon Of Renal Injury) pilot trial to evaluate the performance of its Aortix™ percutaneous mechanical circulatory support (pMCS) device in preventing acute kidney injury (AKI) during cardiac surgery, a common and serious complication that impacts approximately 30% of patients.
-
Procyrion's Aortix Percutaneous Mechanical Circulatory Support Device to be Showcased at TCT 2021 Annual Meeting
11/2/2021
Procyrion, Inc., a medical device company dedicated to improving outcomes for patients with cardiac and renal impairment, announced the schedule of presentations to be featured at the annual Transcatheter Cardiovascular Therapeutics conference in Orlando, Florida from November 4th to November 6th.
-
Procyrion Announces Successful First-in-Human Cases in Cardiorenal Syndrome (CRS) Patients with Aortix™ Percutaneous Mechanical Circulatory Support Device
5/25/2021
Procyrion, Inc., a medical device company dedicated to improving outcomes for patients with cardiac and renal impairment, announced successful treatment of the first patients in the company's pilot trial to evaluate the performance of its novel Aortix™ percutaneous mechanical circulatory support device in patients with cardiorenal syndrome.
-
To date, Procyrion has raised more than $29 million in funding.